# 2026-04491: FDA Sets Clock for ENSACOVE Patent Extension Review

2026-04491, Determination of Regulatory Review Period for Purposes of Patent Extension; ENSACOVE, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-06, effective 2026-03-06; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-04491
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-04491
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; ENSACOVE
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 11075
- Published: 2026-03-06
- Effective: 2026-03-06
- Comments close: 2026-05-05
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Sets Clock for ENSACOVE Patent Extension Review

## Summary

The FDA has officially set the review period for ENSACOVE, a human drug, so its patent holder can apply for extra patent time. This affects the drug company and anyone tracking patent extensions, with deadlines to challenge dates or diligence claims by May 5 and September 2, 2026. It’s a key step to keep innovation protected while making sure the process stays fair and on schedule.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENSACOVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

## Effects PRIA read

- FDA Sets ENSACOVE Review Period: benefit, high. FDA determined ENSACOVE’s regulatory review period is 4,645 days total (4,288 days testing phase and 357 days approval phase). The determination uses an IND effective date of April 2, 2012, an NDA submission date of December 28, 2023, and an approval date of December 18, 2024; the applicant seeks 1…
- Deadline to Seek Redetermination: benefit, low. Anyone who believes the published dates are incorrect may submit electronic or written comments and ask FDA for a redetermination by May 5, 2026. Electronic comments are accepted at https://www.regulations.gov until 11:59 p.m. Eastern Time on May 5, 2026; mailed paper comments must be received by t…
- Deadline to Petition on Due Diligence: benefit, low. Any interested person may petition FDA to determine whether the patent applicant acted with due diligence during the regulatory review period; petitions must be filed by September 2, 2026 and comply with 21 CFR 60.30 and related requirements. Petitions must be timely, follow submission rules in 21…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-04491 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/06/2026-04491/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ensacove)
- [2026-04491 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-06/pdf/2026-04491.pdf)

## Related
- [Previous: 2026-04490, Gulf Fishery Management Council; Public Meeting](https://policyrisk.com/federal-register/2026-04490)
- [Next: 2026-04492, Community Development Financial Institutions Fund; Announcement Type: Notice of…](https://policyrisk.com/federal-register/2026-04492)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-04491 (as of 2026-06-08).
